Flovent

Fluticasone propionate

Clinical data
Trade names	Flixotide (inhalatory), Flixonase and Flonase (nasal)
AHFS/Drugs.com	Monograph
Pregnancy category	US: C (Risk not ruled out) C for Intranasal and Inhaled
Routes of administration	Intranasal, Inhaled, Topical Cream or Ointment
ATC code	D07AC17 (WHO) & D07AC04 (WHO) (topical)
Legal status
Legal status	UK: P (Pharmacy medicines) US: OTC
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal Hepatic (CYP3A4-mediated)
Biological half-life	10 hours
Excretion	Renal
Identifiers
IUPAC name S-(fluoromethyl)-6α,9-difluoro-11β, 17-dihydroxy-16α-methyl-3-oxoandrosta-1, 4-diene-17β-carbothioate, 17-propanoate
CAS Number	80474-14-2 Y
PubChem CID	444036
IUPHAR/BPS	7080
DrugBank	DB00588 Y
ChemSpider	392059 Y
UNII	O2GMZ0LF5W
ChEBI	CHEBI:31441 Y
ChEMBL	CHEMBL1473 Y
ECHA InfoCard	100.129.097
Chemical and physical data
Formula	C25H31F3O5S
Molar mass	500.57 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(SCF)[C@]3(OC(=O)CC)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)\C=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C
InChI InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1 Y Key:WMWTYOKRWGGJOA-CENSZEJFSA-N Y

Fluticasone propionate belongs to a class of drugs known as corticosteroids, specifically glucocorticoids, which are hormones that predominantly affect the metabolism of carbohydrates and, to a lesser extent, fat and protein. It is used to treat asthma, allergic rhinitis, nasal polyps, various skin disorders and Crohn's disease and ulcerative colitis. It is also used to treat eosinophilic esophagitis.

Fluticasone is used by powder or aerosol inhalation for the prophylaxis of asthma, the nasal spray is used for prophylaxis and treatment of allergic rhinitis, nasal drops are used in the treatment of nasal polyps, and creams and ointments are applied topically in the treatment of various skin disorders. It can be given orally in the treatment of Crohn’s disease and ulcerative colitis. Some benefit was also reported in coeliac disease.

If taken correctly, the nasal spray and oral inhaler formulation have less corticosteroid side effects than the tablet formulation because they limit systemic (blood) absorption. However, if the spray or inhaler is used at higher than recommended doses or with other corticosteroids, serious side effects can occur. These systemic corticosteroid side effects include weakened immune system, increased risk of systemic infections, osteoporosis, and elevated pressure in the eyes.

Common side effects may include nasal irritation, headache, nausea, vomiting, diarrhea, nosebleed, and cough. Rare side effects include painful white patches in nose or throat, sore throat, bruising (erythema nodosum), vision problems, swelling of face or neck, and difficulty breathing or swallowing.